NX1 Nexalis Therapeutics Limited
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.
Returns
| 1 day | 0.0% |
| 1 week | 0.0% |
| 1 month | 50.0% |
| 3 months | 50.0% |
| 6 months | -11.8% |
| 1 year | -40.0% |
| 3 years | -65.1% |
Risk
| Volatility (1y ann.) | 137.3% |
| Beta vs ASX 200 | -0.75 |
| Sharpe (1y) | 0.24 |
| VaR 95% (1-day) | -15.8% |
| Max drawdown (1y) | -75.0% |
| Off 1-year high | -58.3% |
Technicals
| RSI(14) | 67 |
| vs 50DMA | 35.6% |
| vs 200DMA | -18.0% |
| Trend | Death cross |
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
- Revenue—
- Gross profit—
- Operating income-$2.47M
- Net income-$1.62M
- Diluted EPS-0.01
- Free cash flow-$888.17K
- Net debt$304.38K